.
MergerLinks Header Logo

Announced

Completed

Ocugen merged with Histogenics Corporation.

Financials

Edit Data
Transaction Value-
Consideration TypeCash
Capital Owned-
Capital Bid For100%
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

Completed

United States

Merger

Medical Services

Majority

regenerative medicine

Public

Acquisition

Friendly

Single Bidder

Synopsis

Edit

Ocugen, a clinical stage biopharmaceutical company, merged with Histogenics Corporation, a regenerative medicine company. Financial terms were not disclosed. “This transaction with Ocugen reflects the continued commitment of our management team and Board of Directors to deliver value to stockholders and make a difference in patients’ lives. Following a thorough review of strategic alternatives for Histogenics and the NeoCart program, we have determined that a merger with Ocugen will enable Histogenics investors to participate in Ocugen’s broader pipeline of ocular disease and gene therapy opportunities, including several late-stage clinical candidates, and a robust preclinical platform. In addition, we plan to continue to evaluate opportunities to realize additional value from the discontinued NeoCart program over the coming weeks.” Adam Gridley, President of Histogenics.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US